USA Assessed the Situation with Vaccination with Johnson & Johnson
OREANDA-NEWS. The suspension of Johnson & Johnson's vaccine use will not have an essential influence on the United States' plans to vaccinate the citizens at large. This was stated on April 13 by the White House Coordinator for Response to the COVID-19 pandemic Jeff Seyenz.
Previously, the US Food and Drug Administration (FDA) and the Centers for Disease Control and Dissemination (CDC) recommended that Johnson & Johnson's Janssen Pharmaceutical Division's Janssen Pharmaceutical Unit suspend vaccination against COVID-19 "for precautionary reasons."
Jeff Seyenz said in a statement: "This announcement will not have a significant impact on our vaccination plan: to date, Johnson & Johnson's vaccine is used in less than 5% of all registered vaccinations."
The New York Times, citing authorities, wrote that cases of blood clots after vaccination were detected in six women aged 18 to 48 years. One died, another was hospitalized in critical condition.
According to the CDC, about seven million US citizens have already received the Johnson & Johnson vaccine.
Previously, the FDA indicated that it has not yet identified a link between the Johnson & Johnson vaccine and thrombosis, and has reported only three alarming cases to its European colleagues. Other US regulators have expressed concern over surveillance of the vaccine campaign.
The Advisory Committee on Immunization Practices (ACIP) is about to meet with CDC to assess potential risks.
The European Medicines Agency, EMA, has begun to study new information on the J&J vaccine. The organization says it is aware of four episodes of complications outside the EU, one of them fatal.